HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Development of an ELISA for the detection of 2-nitroimidazole hypoxia markers bound to tumor tissue.

Abstract
Canine and rodent tumors covalently bind the fluorinated 2-nitroimidazole, CCI-103F, in a way that immunohistochemical analysis shows is consistent with the location of tumor hypoxia. We have now developed a rapid, quantitative, and non-radioactive enzyme linked immunosorbent assay for the binding of CCI-103F in biopsy samples of spontaneous canine tumors. Issues of antigen stability during tissue processing, calibration of the ELISA, and the use of biopsy samples for measuring tumor hypoxia by the ELISA approach are addressed.
AuthorsJ A Raleigh, E M Zeman, M Rathman, J K LaDine, J M Cline, D E Thrall
JournalInternational journal of radiation oncology, biology, physics (Int J Radiat Oncol Biol Phys) Vol. 22 Issue 3 Pg. 403-5 ( 1992) ISSN: 0360-3016 [Print] United States
PMID1310494 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Nitroimidazoles
  • CCI 103F
Topics
  • Animals
  • Cell Hypoxia (physiology)
  • Dogs
  • Enzyme-Linked Immunosorbent Assay
  • Liposarcoma (physiopathology, veterinary)
  • Neoplasms (physiopathology, veterinary)
  • Nitroimidazoles (metabolism)
  • Sarcoma, Synovial (physiopathology, veterinary)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: